{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:00:16Z","timestamp":1773093616131,"version":"3.50.1"},"reference-count":40,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY027749"],"award-info":[{"award-number":["R01EY027749"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R24EY028764"],"award-info":[{"award-number":["R24EY028764"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R43EY031238"],"award-info":[{"award-number":["R43EY031238"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R43EY031643"],"award-info":[{"award-number":["R43EY031643"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R43EY032827"],"award-info":[{"award-number":["R43EY032827"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R41EY027665"],"award-info":[{"award-number":["R41EY027665"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-18-IBS-172"],"award-info":[{"award-number":["1-18-IBS-172"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The retinopathy of prematurity (ROP), a neovascular retinal disorder presenting in premature infants, is the leading causes of blindness in children. Currently, there is no approved drug therapy for ROP in the U.S., highlighting the urgent unmet clinical need for a novel therapeutic to treat the disease. Secretogranin III (Scg3) was recently identified as a disease-selective angiogenic factor, and Scg3-neutralizing monoclonal antibodies were reported to alleviate pathological retinal neovascularization in mouse models. In this study, we characterized the efficacy and safety of a full-length humanized anti-Scg3 antibody (hAb) to ameliorate retinal pathology in oxygen-induced retinopathy (OIR) mice, a surrogate model of ROP, by implementing histological and functional analyses. Our results demonstrate that the anti-Scg3 hAb outperforms the vascular endothelial growth factor inhibitor aflibercept in terms of efficacy and safety to treat OIR mice. Our findings support the development of anti-Scg3 hAb for clinical application.<\/jats:p>","DOI":"10.3390\/ijms23010350","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T08:12:15Z","timestamp":1640765535000},"page":"350","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6589-7910","authenticated-orcid":false,"given":"Ye","family":"He","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL 33136, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tian","sequence":"additional","affiliation":[{"name":"Everglades Biopharma, LLC, Houston, TX 77054, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-883X","authenticated-orcid":false,"given":"Chang","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL 33136, USA"},{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL 33136, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-2797","authenticated-orcid":false,"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300392, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Webster","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL 33136, USA"},{"name":"Everglades Biopharma, LLC, Houston, TX 77054, USA"},{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-8764","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL 33136, USA"},{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of Prematurity","volume":"382","author":"Smith","year":"2013","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity: Report on Fluorescein Angiographic Findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1167\/iovs.13-13397","article-title":"Effects of Anti-VEGF Treatment on the Recovery of the Developing Retina Following Oxygen-Induced Retinopathy","volume":"55","author":"Tokunaga","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1167\/iovs.10-6798","article-title":"Effect of VEGF Trap on Normal Retinal Vascular Development and Oxygen-Induced Retinopathy in the Dog","volume":"52","author":"Lutty","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10456-019-09662-4","article-title":"Anti-Secretogranin III Therapy of Oxygen-Induced Retinopathy with Optimal Safety","volume":"22","author":"Tang","year":"2019","journal-title":"Angiogenesis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants with Retinopathy of Prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum Levels of Vascular Endothelial Growth Factor and Related Factors after Intravitreous Bevacizumab Injection for Retinopathy of Prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in Systemic Vascular Endothelial Growth Factor Levels after Intravitreal Injection of Aflibercept in Infants with Retinopathy of Prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2985161","DOI":"10.1155\/2019\/2985161","article-title":"Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity","volume":"2019","author":"Chen","year":"2019","journal-title":"J. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus Laser Therapy for the Treatment of Very Low Birthweight Infants with Retinopathy of Prematurity (RAINBOW): An Open-Label Randomised Controlled Trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1084\/jem.20161802","article-title":"Secretogranin III as a Disease-Associated Ligand for Antiangiogenic Therapy of Diabetic Retinopathy","volume":"214","author":"LeBlanc","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ophtha.2017.09.020","article-title":"Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity","volume":"125","author":"Vogel","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaapos.2017.06.024","article-title":"Macular Morphology Following Unilateral Bevacizumab Injection for Retinopathy of Prematurity: An OCT Study","volume":"21","author":"Clark","year":"2017","journal-title":"J. AAPOS"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum Concentrations of Vascular Endothelial Growth Factor in an Infant Treated with Ranibizumab for Retinopathy of Prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41372-020-00884-9","article-title":"Neurodevelopmental Outcomes Following Bevacizumab Treatment for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis","volume":"41","author":"Kaushal","year":"2020","journal-title":"J. Perinatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e20183537","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"ref_19","first-page":"345","article-title":"Neutralizing Antibody to VEGF Reduces Intravitreous Neovascularization and May Not Interfere with Ongoing Intraretinal Vascularization in a Rat Model of Retinopathy of Prematurity","volume":"14","author":"Geisen","year":"2008","journal-title":"Mol. Vis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1167\/iovs.13-11625","article-title":"Anti-VEGF Antibody Leads to Later Atypical Intravitreous Neovascularization and Activation of Angiogenic Pathways in a Rat Model of Retinopathy of Prematurity","volume":"54","author":"McCloskey","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/02713683.2018.1542736","article-title":"Intravitreal Delivery of VEGF-A165-Loaded PLGA Microparticles Reduces Retinal Vaso-Obliteration in an In Vivo Mouse Model of Retinopathy of Prematurity","volume":"44","author":"Wang","year":"2019","journal-title":"Curr. Eye Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.survophthal.2009.02.021","article-title":"Plus Disease","volume":"54","author":"Davitt","year":"2009","journal-title":"Surv. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1167\/iovs.08-1780","article-title":"Neutralizing VEGF Decreases Tortuosity and Alters Endothelial Cell Division Orientation in Arterioles and Veins in a Rat Model of ROP: Relevance to plus Disease","volume":"49","author":"Hartnett","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/0974-9233.63080","article-title":"Plus Disease: Why Is It Important in Retinopathy of Prematurity?","volume":"17","author":"Solarte","year":"2010","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1167\/iovs.06-0733","article-title":"The Pattern Electroretinogram as a Tool to Monitor Progressive Retinal Ganglion Cell Dysfunction in the DBA\/2J Mouse Model of Glaucoma","volume":"48","author":"Porciatti","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Brandli, A., and Stone, J. (2015). Using the Electroretinogram to Assess Function in the Rodent Retina and the Protective Effects of Remote Limb Ischemic Preconditioning. J. Vis. Exp., e52658.","DOI":"10.3791\/52658-v"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2218","DOI":"10.21769\/BioProtoc.2218","article-title":"Assessment of Murine Retinal Function by Electroretinography","volume":"7","author":"Benchorin","year":"2017","journal-title":"Bio. Protoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/EB.S94447","article-title":"Revisiting the Mouse Model of Oxygen-Induced Retinopathy","volume":"8","author":"Kim","year":"2016","journal-title":"Eye Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/nprot.2009.187","article-title":"Quantification of Oxygen-Induced Retinopathy in the Mouse: A Model of Vessel Loss, Vessel Regrowth and Pathological Angiogenesis","volume":"4","author":"Connor","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Nakamura, S., Imai, S., Ogishima, H., Tsuruma, K., Shimazawa, M., and Hara, H. (2012). Morphological and Functional Changes in the Retina after Chronic Oxygen-Induced Retinopathy. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032167"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8936","DOI":"10.1523\/JNEUROSCI.18-21-08936.1998","article-title":"The Major Cell Populations of the Mouse Retina","volume":"18","author":"Jeon","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1755-3768.2010.01963.x","article-title":"Structural Consequences after Intravitreal Bevacizumab Injection without Increasing Apoptotic Cell Death in a Retinopathy of Prematurity Mouse Model","volume":"90","author":"Akkoyun","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1167\/iovs.06-0828","article-title":"Preclinical Safety Evaluation of Intravitreal Injection of Full-Length Humanized Vascular Endothelial Growth Factor Antibody in Rabbit Eyes","volume":"48","author":"Inan","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1167\/iovs.08-2871","article-title":"Comparative Evaluation of Apoptotic Activity in Photoreceptor Cells after Intravitreal Injection of Bevacizumab and Pegaptanib Sodium in Rabbits","volume":"50","author":"Avci","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1073\/pnas.1301331110","article-title":"Anti-VEGF- and Anti-VEGF Receptor-Induced Vascular Alteration in Mouse Healthy Tissues","volume":"110","author":"Yang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"BEAT-ROP Cooperative Group Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, Randomized Trial Comparing Bevacizumab plus Fluorouracil (FU)\/Leucovorin (LV) with FU\/LV Alone in Patients with Metastatic Colorectal Cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/OPX.0000000000000941","article-title":"In Vivo Angiography Quantifies Oxygen-Induced Retinopathy Vascular Recovery","volume":"93","year":"2016","journal-title":"Optom. Vis. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3109\/02713683.2015.1083588","article-title":"Defining the Relationships Among Retinal Function, Layer Thickness and Visual Behavior During Oxidative Stress-Induced Retinal Degeneration","volume":"41","author":"Patel","year":"2016","journal-title":"Curr. Eye. Res."},{"key":"ref_40","unstructured":"Kokona, D., Jovanovic, J., Ebneter, A., and Zinkernagel, M.S. (2017). In Vivo Imaging of Cx3cr1gfp\/Gfp Reporter Mice with Spectral-Domain Optical Coherence Tomography and Scanning Laser Ophthalmoscopy. J. Vis. Exp."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/350\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:55:24Z","timestamp":1760169324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ijms23010350"],"URL":"https:\/\/doi.org\/10.3390\/ijms23010350","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,29]]}}}